Buy & Sell Newmont Corporation (NEM) – Newmont Corporation Price Today
Key Stats
- $116.43BMarket Cap
- Basic MaterialsSector
- -26.31%3M Drawdown
- $113.18BEnterprise Value
- 0.95%Dividend Yield
- 48% Buy | 52% SellTrading Activity
- 48 daysTypical Hold Time
Newmont Corporation (NEM) is currently valued at a market capitalization of $116.43B, with an enterprise value of $113.18B. Over the past 52 weeks, Newmont Corporation has traded between a low of $50.1 and a high of $131.95, highlighting its annual price range. Over the past three months, Newmont Corporation has recorded a drawdown of -26.31%, reflecting recent price volatility. Newmont Corporation offers a dividend yield of 0.95%, with the most recent dividend of $0.26 paid on 03 Mar 26. On average, investors hold Newmont Corporation for approximately 48 days, indicating typical investor behavior on the platform.
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
